(CercleFinance.com) – Novo Nordisk has announced the completion of the acquisition of Dicerna Pharmaceuticals.
Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all of the outstanding common shares of Dicerna at a price of USD 38.25 per share.
Novo Nordisk has been informed by the custodian of the tender offer that a total of approximately 64,946,526 ordinary shares of Dicerna have been validly tendered, which represents approximately 82.6% of the total number of ordinary shares of Dicerna. Dicerna in circulation.
Upon completion of the merger, Dicerna became a wholly-owned subsidiary of Novo Nordisk. Dicerna common stock will no longer be listed or traded on the Nasdaq Global Select Market.
Copyright © 2021 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
